Santos, R. Kelly prosecutor rejoins law firm Cleary from Brooklyn US attorney's office
May 12 (Reuters) - Breon Peace, who as Brooklyn's U.S. attorney prosecuted R&B singer R. Kelly and former Republican U.S. Representative George Santos, has rejoined Cleary Gottlieb Steen & Hamilton as a partner, the law firm said Monday.
Peace, who served as U.S. attorney for the Eastern District of New York under Democratic President Joe Biden, resigned days before Republican President Donald Trump was inaugurated in January.
Joseph Nocella Jr., a Nassau County judge who is Trump's nominee to replace Pearce, was sworn in as interim U.S. attorney last week.
Nocella's nomination is currently pending before the U.S. Senate Judiciary Committee, as is Trump's pick to lead the neighboring Southern District of New York, former U.S. Securities and Exchange Commission chair Jay Clayton.
Under Peace's tenure, the Eastern District obtained a 30-year prison sentence for Kelly for sex crimes and racketeering, and secured Santos' guilty plea for fraud and identity theft. Prosecutors argued last month that Santos should receive more than seven years in prison.
Peace's office also won the conviction of Ozy Media founder Carlos Watson for defrauding investors in his now-defunct startup. Trump commuted Watson's nearly 10-year prison sentence in March.
The office under Peace secured the conviction of former Mexican security minister Genaro Garcia Luna on charges of taking bribes from the drug cartels he was supposed to fight. Garcia Luna was sentenced to more than 38 years in prison in October.
Peace disclosed in 2021 as part of his nomination that he earned more than $4 million from Cleary since 2020. At the time, his clients included HSBC Bank, BNP Paribas, Citigroup, Morgan Stanley, American Airlines, PricewaterhouseCoopers and Whirlpool.
He will co-lead the law firm's litigation group, Cleary said in Monday's announcement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
42 minutes ago
- Reuters
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
CHICAGO, June 1 (Reuters) - Treating breast cancer patients with AstraZeneca's (AZN.L), opens new tab experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding that could change the way such cancers are treated, cancer experts said on Sunday. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumor growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in the risk of disease progression or death, said Dr. Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky believes the data will likely result in a new treatment paradigm. The trial involved 3,256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as estrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' (NOVN.S), opens new tab Kisqali, Pfizer's (PFE.N), opens new tab Ibrance or Lilly's (LLY.N), opens new tab Verzenio, which block an enzyme that fuels cancer growth. About 40% of patients treated with aromatase inhibitors develop mutations in the estrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called Selective Estrogen Receptor Degraders (SERDS) block estrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to look for ESR1 mutations until 315 patients were identified. They were randomly assigned to either switch to camizestrant plus the CDK4/6 inhibitor (157 patients) or continue with standard treatment plus a placebo (158 patients). The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr. Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Separately, adding AstraZeneca's immunotherapy durvalumab to standard treatment before and after surgery in patients with early-stage stomach and esophageal cancers helped extend the time patients had without cancer progression or recurrence compared to chemotherapy alone. The global study of nearly 950 patients tested durvalumab, sold under the brand Imfinzi, in combination with a chemotherapy regimen called FLOT given around the time of initial cancer surgery. Patients in the durvalumab plus FLOT arm experienced a 29% better event-free survival than those who received the chemotherapy regimen. "We demonstrate that immunotherapy works in early-stage disease, which is great," lead study author Dr. Yelena Jarnigan of Memorial Sloan Kettering Cancer Center in New York told reporters at the meeting. "We did not see any new safety signals, so this will change practice for our patients, which is exciting to see." Both studies were published on Sunday in the New England Journal of Medicine.
The Independent
44 minutes ago
- The Independent
Catholic students find refuge at Princeton University's worship space and cheer new pope
While other students might be in class or socializing at lunch, a group of young Catholics attends Mass every weekday at noon at the Princeton University Chapel. They sing Gregorian chants in Latin, pray and receive Communion at a side chapel — inside the huge, nondenominational Princeton Chapel — that young, devoted Catholics see as a sacred refuge in a mostly liberal and secular Ivy League environment. 'I feel that people's faith is so strong here,' student Logan Nelson said of the dedicated Catholic space where he attends daily Mass. 'It feels like a home — even more so than my own house.' A tight-knit Catholic campus ministry at a historic chapel The Gothic university chapel was built in 1928. At the time, Princeton says, its capacity to seat more than 2,000 people was second in size only to King's College Chapel at Cambridge University. Today, the chapel hosts interfaith services, concerts and weddings throughout the academic year and is known by the university as 'the bridge between town and gown.' On May 8, Catholic students were worshipping as usual at daily Mass in the side chapel when the service was interrupted by news alerts on their phones. In the Vatican, white smoke billowed from the Sistine Chapel, indicating that a new leader of their faith had been elected. The Rev. Zachary Swantek, Princeton's Catholic chaplain, told the group to gather at the Catholic Ministry office. Together, they watched on TV as the election of the first U.S.-born pope was announced. 'It was electric,' Nelson said, adding there was 'uproar' in the room when Chicago-born Cardinal Robert Prevost became the 267th pontiff. 'It was so cool to see an American pope.' Like other members of the Catholic ministry, he is hopeful that Pope Leo XIV will help bring a revival for Catholicism in America. 'I feel that there's a resurgence of Catholicism today,' said Nelson, who was religiously unaffiliated until last year when he converted to Catholicism. 'You see people who are passionate about their faith. There's a new wave coming, and we're going to have more converts like me, who are coming from the 'nones.'' Across much of the world, the number of people who are nonbelievers or unaffiliated with any organized religion has dramatically increased over the years. The people known as 'nones' — atheists, agnostics, or nothing in particular — comprise 30% or more of the adult population in the U.S., according to a survey by The Associated Press-NORC Center for Public Affairs Research. Princeton's Office of Religious Life says it supports members of the school community 'of any religious identity or of none.' Being a devoted Catholic on a mostly secular campus can be challenging; Swantek says he's never felt 'more needed as a priest.' He is proud of the tight-knit, welcoming Catholic community that he leads, and how they've helped recent converts come into the faith. A U.S.-born pope becomes a sign of hope for American Catholics News of the first U.S.-born pope was welcomed by Catholics across the ideological spectrum in Pope Leo XIV 's homeland. 'Something that did bring me a lot of hope is Pope Leo has a missionary background,' said Ace Acuna, a Princeton alumni. He recently attended a Mass at the chapel before beginning a nearly five-week Catholic pilgrimage from Indianapolis to Los Angeles. 'In a world where in some places it might look like faith is on the decline, a church that's willing to go out to the margins and evangelize and be on mission, that's going to be so important,' Acuna said. When he was an undergrad at Princeton, Acuna said the chapel became crucial to his college life. On his way to class every morning, he'd pass by the chapel for a silent prayer. He'd return for the noon Mass and again at the end of the day for one last prayer. 'Princeton is a very busy place and there's a lot of noise both externally but also internally because we're so busy and we're always worried about the next thing,' he said. 'Sometimes you just want silence, and you just want a place where you can lay down your burdens.' At the close of one recent Mass, David Kim and his girlfriend Savannah Nichols continued to pray near the altar, holding hands, kneeling or prostrating on the floor in a sign of reverence. Kim, a recent graduate of the Princeton Theological Seminary, converted to Catholicism last year and has been serving as an altar server at the Princeton University chapel. He called the chapel's side altar "an island of Christian life in an unbelieving world.' Princeton University has always had a vibrant religious community and a religiously diverse one, said Eric Gregory, a professor of religion there. 'In a way it's either so secular or even post-secular that it's not threatened by the Christian presence on campus,' he said. "Religious students in our campus are not cloistered from campus. They're also in sports teams, clubs and the newspaper. They're integrated.' Catholics students in Leo's home state cheer his election Catholics at the the University of Illinois at Urbana-Champaign were elated by his election — and reinvigorated in practicing their faith. 'Being able to live out my faith in this extremely secular campus is such a blessing to me,' said student Daniel Vanisko, a lifelong Catholic, later adding in an email that the pope's election 'really helps me to draw closer to my faith, seeing that someone that grew up in the same state as me, is the successor of Peter in the Church." Cavan Morber, a rising junior, said attending UIUC 'gives me chance to be challenged in my beliefs, think critically about what I believe, and share my faith with others.' Asked in an email exchange about the pope's election, Morber replied: 'What a time to be alive!' 'I am hopeful for how he will be able to unite the Church in a time of a lot of division among Catholics and everyone around the world,' Morber added. ___ Associated Press religion coverage receives support through the AP's collaboration with The Conversation US, with funding from Lilly Endowment Inc. The AP is solely responsible for this content.
Reuters
an hour ago
- Reuters
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
CHICAGO, June 1 (Reuters) - A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment options, researchers reported on Sunday. The study, presented at the American Society of Clinical Oncology meeting in Chicago and published in Nature Medicine, is the latest among several efforts testing next-generation chimeric antigen receptor T-cell or CAR-T treatments, a type of immunotherapy in which patients' immune cells are engineered to recognize and kill cancer cells. The work, from researchers at the University of Pennsylvania and Gilead's (GILD.O), opens new tab Kite cell therapy unit, tested a dual CAR-T treatment in an effort to overcome the defenses of glioblastoma, the most common brain tumor in adults. CAR-T therapy is already used to treat blood cancers including leukemia, lymphoma and multiple myeloma, and those treatments typically only take aim at one target on the tumor. But solid tumors such as glioblastoma tend to have multiple subpopulations of tumor cells, suggesting that treatments will need more than one target to succeed, said University of Pennsylvania researcher Dr. Stephen Bagley, who led the study. For the treatment, which is injected directly into spinal fluid, the team selected EGFR, which is found in 50% to 60% of all glioblastoma tumors, and a second target called interleukin-13 receptor alpha 2, found in an estimated 75% of glioblastoma tumors. Typically, advanced glioblastoma patients whose cancers return after initial treatment with surgery, radiation and chemotherapy live six to 10 months. Interim results of just six patients were published in March 2024 in Nature Medicine, opens new tab. The current study now includes 18 patients treated with the experimental therapy after their tumors returned following standard treatment. Of these, only 13 had a measurable tumor at the time the cells were introduced, and of those, eight, or 62%, had their tumors shrink, Bagley said. "That was pretty remarkable to us because historically for recurrent glioblastoma tumors, we usually don't see anything shrink them." Several patients lived 12 months or longer, and in one patient, the disease remained stable for 16 months. But so far, the benefit is largely temporary, with many patients relapsing two to three months later. Most patients experienced fevers and neurotoxicity such as lethargy or confusion for two or three days after the cells are injected, but the side effects were manageable, Bagley said. Cindy Perettie, executive vice president of Gilead's Kite cell therapy unit, said she is encouraged by the 62% response. "What we didn't see that we wanted to in a majority of the patients was persistence," she said. Kite is working to develop a third target that will allow the drug to remain in the brain longer. "We will be putting that construct into the clinic sometime next year," she said. Meanwhile, the team wants to test the therapy in 12 patients with newly diagnosed disease. "We know patients in the frontline setting are going to be healthier," she said, and the hope is to see more persistent results. Demand for the trial has been great. Perettie estimates there are 10 times as many patients seeking enrollment for every open slot, and some doctors are referring patients from as far away as Hawaii. "Today, there's only one approved therapy outside of radiation, so for these patients, this is really exciting to see any kind of response," she said. Kite hopes to expand to three or four centers with its triple-target version of the product. "I think we're on the right track," Bagley said, adding that he believes there will be longer-lasting treatments in the next few years.
